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In vivo expression of an aberrant MYB-GATA1 fusion induces leukemia in the presence of GATA1 reduced levels Chromosomal rearrangements are frequently found in hematological malignancies. 1 Transgenic expression of the generated aberrant transcripts and corresponding fusion proteins often induces leukemia in mice, suggesting a role in disease onset. 2 The MYB gene, on human chromosome 6, corresponds to a 75-kDa transcription factor exerting a physiological function in the hematopoietic system (reviewed in Ramsay and Gonda 3 ). GATA1, a nuclear protein with an essential role in hematopoiesis, is coded by a gene located on the human X chromosome (reviewed in Shimizu et al. 4 ). A specific and complementary cross talk between these two factors has been observed in hematopoietic maturation. High levels of MYB and low levels of GATA1 characterize the early stages of hematopoiesis: as differentiation progresses, an inverse regulation takes place ultimately leading to high levels of GATA1 and low levels of MYB in terminally differentiated cells. 3 The role of MYB and GATA1 has been explored through various in vivo studies. Several animal models that expressed reduced levels of GATA1 were used to study the effects of its deficiency. Interestingly, expression of the GATA1 low allele, as obtained in one GATA1 genetically impaired mouse model, results in anemia and thrombocytopenia, 5 and eventually into a disease closely resembling human idiophatic myelofibrosis. 6 We identified in an acute myeloid leukemia-M5 patient (see Supplementary Information) a rare chromosomal rearrangement (t(X;6)(p11.2; q23)), which results in a MYB-GATA1 fusion product. We have studied this aberrant product in mice expressing reduced levels of GATA1 and found that it is able to induce leukemia, although with reduced penetrance and long latency.
To characterize this genomic alteration, we carried out fluorescence in situ hybridization as well as 3 0 -rapid amplification of cDNA ends PCR experiments, precisely positioning the two breakpoints (bps) and cloning a MYB-GATA1 fusion transcript (Figure 1i ; for details see the Supplementary Materials and Supplementary Figure 1) . We observed that an X chromosome internal inversion, associated with its translocation to chromosome 6, had occurred, as explained and illustrated in Supplementary Figure 2 . Owing to GATA1 localization on the X chromosome and the fact that our patient was a male, the rearrangement resulted in the creation of the aberrant fusion transcript, complete loss of the normal GATA1 gene, and lack of a reciprocal fusion transcript, as one would expect in the presence of a balanced translocation. Gene expression analysis with MYB and GATA1-specific probes reflected the genomic rearrangement (Figure 1ii) , showing loss of wild type (WT) GATA1, overexpression of MYB and high levels of the fusion transcript. These results are in accordance with what is known about the reciprocal regulation of MYB and GATA1, the latter exerting a negative control on the promoter of MYB. In fact, in the absence of a functional GATA1, an increase in both MYB WT and MYB-GATA1 expression is expected, as these genes are directed by the same promoter. At the same time, the lack of the negative regulatory domain of the MYB gene in the MYB-GATA1 fusion product (Figure 1i ) might contribute to enhancing the expression of the corresponding transcript, as shown by the GATAe5-6 and MYBe2-3 versus MYBe8-9 probes (Figure 1ii ).
We then decided to test the leukemogenic potential of this new fusion product in vivo. We cloned the aberrant transcript into a PINCO retroviral vector, which we used to transduce lin À bone marrow cells, derived from either WT or p53 À/À mice. After sorting, infected cells were used to reconstitute lethally irradiated WT-recipient mice (data not shown). None of the WT-reconstituted mice developed any sign of hematological disease. At the same time, p53
À/À -transduced mice developed thymic lymphoma, after a mean period of 128 days, consistent with the lack of Tp53. This result was compatible with the presence of the GATA1 WT allele in the bone marrow of the reconstituted mice. Indeed, this situation did not reproduce exactly that of the patient studied, who completely lacked a normal GATA1 allele. Interestingly, some of the phenotypic features of our patient (including anemia and thrombocytopenia) closely resembled those of the mice expressing reduced levels of GATA1. Therefore, to better mimic loss of GATA1 expression, we took advantage of the GATA1 low mouse model described by Shivdasani et al. 5 We repeated the same experiment using lin À cells from the bone marrow of GATA1 low mice (either GATA1 low/Y males or GATA1 low/low females), transduced with either PINCO-ev or PINCO-MYB-GATA1, in WT lethally irradiated recipients. Reduced levels of GATA1 were confirmed by RQ-PCR on spleen cells from GATA1 low mice (not shown). As expected, because of the reduced levels of GATA1, all the reconstituted mice were anemic and moderately thrombocytopenic, as already described, 5 with mean hemoglobin levels 6.58 and 6.36 g/dl (normal range: 11.0-15.1 g/dl), red blood cell counts 3.9 Â 10 3 /ml and 4.0 Â 10 3 /ml (normal range: 6.36-9.42 Â 10 3 /ml) and platelet counts 445.3 Â 10 3 /ml and 554.3 Â 10 3 /ml (normal range: 592-2972 Â 10 3 /ml) in the GATA1 low -PINCO-ev and GATA1
low -PINCO-MYB-GATA1 mice, respectively (Supplementary Table 1 ). All five PINCO-MYB-GATA1 mice in a GATA low background showed phenotypic features resembling those considered typical of the myelodyplastic syndrome spectrum, such as pancytopenia, red blood cells abnormalities (anisocytosis and poikilocytosis with presence of dacrocytes) and presence of dysplastic cells Letters to the Editor passage (see Supplementary Figure 6 ). Peripheral blood smears ( Figure 2iii ) as well as immunophenotypic analysis of peripheral blood and bone marrow cells of transplanted animals (not shown) confirmed the pattern observed in the mMG1 mouse. Moreover, reverse transcription-PCR with primers specific for the MYB-GATA1 transcript confirmed that the fusion product was expressed in the GATA1 low -PINCO-MYB-GATA1 mice (see Supplementary Information for details) .
Our results indicate that the MYB-GATA1 chimeric product, in a GATA1 low background, induces leukemia, albeit with a low penetrance, as well as myelodyplastic syndrome-resembling phenotypes. The importance of MYB and GATA1 in the normal hematopoietic tissue as well as for the onset of hematological malignancies has been extensively studied. 3, 4 Deregulation of MYB expression has been suggested as a relevant occurence in the proliferation of human malignancies, possibly affecting over 80 MYB target genes. Specific genomic abnormalities have been reported in T-cell acute lymphoblastic leukemia, 3 resulting in either a cryptic duplication within the MYB locus or a t(6;7)(q23;q34) rearrangement, juxtaposing TCRB and MYB in a new chimeric product. Moreover, a t(6;9)(q22-23;p23-24) has been recently described 7 in adenoid cystic carcinoma, with consequent formation of a chimeric MYB-NFIB transcript. This fusion product lacked the 3 0 end of MYB, which contains binding sites for several microRNA, including some that negatively regulate MYB expression: accordingly, the gene was overexpressed. At the same time, in the Gata1G1.05/ þ mouse model, GATA1 reduced levels have been described as predisposing to leukemia onset and GATA1 mutations have been detected in different human cases showing altered Letters to the Editor hematopoietic phenotypes, including anemia, thrombocytopenia and megakaryoblastic leukemia. 4 The t(X;6)(p11;q23) rearrangement has been already described in few previous cases, although the corresponding bps have not been cloned. In particular, Dastugue et al. described two infant patients, 8 affected by acute basophilic leukemia (see Supplementary Table  2 for the comparison of the two patients with our case). We do not have enough elements to assess the presence of a similar leukemia in our patient, who showed a very aggressive phenotype, as confirmed by the lack of a response to treatment. Our study, by demonstrating that the rearrangement affects both MYB and GATA1, confirms their role in hematological malignancies, suggests that the aberrant MYB-GATA1 fusion contributes to leukemogenesis and hints at a possible cooperative function of these two factors in the oncogenic process.
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